远距病患监护设备市场、机会、成长动力、产业趋势分析与预测，2024-2032 年

从 2024 年到 2032 年，全球远端患者监护设备市场的复合年增长率将超过 11.7%。 RPM 设备有助于在传统临床环境之外对患者健康状况进行持续、即时监测。糖尿病、心血管疾病、癌症和慢性肾臟病 (CKD) 等慢性疾病的盛行率激增，大大推动了远距患者监护设备产业的成长。

例如，世界心臟联合会(WHF) 的报告强调，2021 年全球心血管疾病(CVD) 死亡人数将达到2,050 万人。在低收入人群中。

远端患者监护设备市场根据产品、应用、最终用途和地区进行分组。

市场将产品分为心臟、血压、神经、多参数、血糖、胎儿和新生儿、睡眠监测设备等。远距患者监护设备产业的心臟设备部分预计到 2032 年将达到 98 亿美元。透过识别心律不整或心臟病等疾病的早期迹象，这些设备不仅可以提高治疗成功率，还可以减轻严重的併发症。此外，借助先进的传感器和演算法，现代心臟设备可确保精确的指标捕获，使医疗保健提供者能够做出明智的、量身定制的治疗决策，从而推动远端患者监护设备市场的成长。

RPM设备的应用领域包括心血管疾病、癌症、糖尿病、神经系统疾病、传染病、呼吸系统疾病等。 2023 年，光是心血管疾病领域就占了 30 亿美元。鑑于包括高血压和心臟衰竭在内的心血管疾病是全球发病率和死亡率最高的原因之一，因此持续监测的必要性变得至关重要。 RPM 设备透过提供即时监控，不仅可以及早发现异常情况，还可以预见潜在的併发症，从而能够及时进行干预。这些功能不仅可以预防严重后果，还可以减少住院治疗，进一步推动市场成长。

到 2032 年，美国远距病患监护设备市场预计将达到资料亿美元。设备的发展和实施。加拿大公共卫生局强调，糖尿病盛行率激增，2021 年该国 9.4% 的人口（370 万人）被诊断出糖尿病，性别差异显着，这进一步加剧了远端患者监测设备产业的扩张轨迹。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 全球慢性病发生率上升
    • 新兴国家可支配收入和医疗保健支出不断增长
    • 已开发国家的技术进步
    • 越来越多采用远距患者监护设备
  • 产业陷阱与挑战
    • 设备成本高
    • 严格的监管框架
• 成长潜力分析
• 技术景观
• 监管环境
• 波特的分析
• PESTEL分析

第 4 章：竞争格局

• 介绍
• 公司市占率分析
• 有竞争力的仪表板
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 战略展望矩阵

第 5 章：市场估计与预测：按产品分类，2021 - 2032 年

• 主要趋势
• 心臟监测设备
• 血压监测装置
• 神经监测设备
• 呼吸监测设备
• 多参数监测装置
• 血糖监测设备
• 胎儿和新生儿监测设备
• 睡眠监测设备
• 其他监控设备

第 6 章：市场估计与预测：按应用分类，2021 - 2032

• 主要趋势
• 心血管疾病
• 癌症
• 糖尿病
• 神经系统疾病
• 传染病
• 呼吸系统疾病
• 其他应用

第 7 章：市场估计与预测：按最终用途，2021 - 2032 年

• 主要趋势
• 居家照护环境
• 长期照护
• 其他最终用户

第 8 章：市场估计与预测：按地区，2021 - 2032

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 俄罗斯
  • 波兰
  • 瑞士
  • 荷兰
  • 欧洲其他地区
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
  • 泰国
  • 印尼
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 哥伦比亚
  • 智利
  • 拉丁美洲其他地区
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋
  • 以色列
  • 中东和非洲其他地区

第 9 章：公司简介

• Abbott Laboratories
• Cerner Corporation
• Baxter International Inc.
• Boston Scientific Corporation
• DexCom, Inc.
• F. Hoffmann-La Roche Ltd
• General Electric Company
• Johnson and Johnson
• Koninklijke Philips NV
• Medtronic plc
• OMRON Corporation
• Siemens Healthineers AG
• VitalConnect

The Global Remote Patient Monitoring Devices Market will show over 11.7% CAGR from 2024 to 2032. RPM devices facilitate the continuous, real-time monitoring of patient's health outside conventional clinical environments. The surging prevalence of chronic ailments, including diabetes, cardiovascular diseases, cancer, and chronic kidney disease (CKD), significantly propels the growth of the remote patient monitoring devices industry.

For instance, a report from the World Heart Federation (WHF) highlighted those global fatalities from cardiovascular diseases (CVD) reached 20.5 million in 2021. CVD topped the global mortality chart in 2021, with a staggering 80% of these deaths occurring in low- and middle-income nations.

The Remote Patient Monitoring Devices Market is grouped based on product, application, end use , and region.

The market categorizes products into cardiac, blood pressure, neurological, multiparameter, blood glucose, fetal and neonatal, sleep monitoring devices, and others. The cardiac devices segment of the remote patient monitoring devices industry is projected to hit USD 9.8 billion by 2032. These devices monitor heart rhythms and rates in real-time, ensuring prompt medical intervention when anomalies arise. By identifying early signs of conditions like arrhythmias or heart attacks, these devices not only enhance treatment success rates but also mitigate severe complications. Furthermore, with advanced sensors and algorithms, modern cardiac devices ensure precise metric capture, empowering healthcare providers to make informed, tailored treatment decisions, thus fueling remote patient monitoring devices market growth.

The application segment of RPM devices encompasses cardiovascular diseases, cancer, diabetes, neurological disorders, infectious diseases, respiratory ailments, and more. In 2023, the cardiovascular diseases segment alone accounted for a substantial USD 3 billion. Given that CVDs, including hypertension and heart failure, rank among the top global morbidity and mortality causes, the need for continuous monitoring becomes paramount. RPM devices, by offering real-time monitoring, not only detect abnormalities early but also foresee potential complications, enabling timely interventions. Such capabilities not only prevent severe outcomes but also reduce hospitalizations, further propelling market growth.

The U.S. remote patient monitoring devices market is on track to reach USD 14.8 billion by 2032. As a frontrunner in technological advancements, the U.S. boasts a robust infrastructure-comprising high-speed internet, advanced data centers, and state-of-the-art technology platforms-that nurtures the evolution and implementation of sophisticated RPM devices. The surging diabetes prevalence, highlighted by the Public Health Agency of Canada, where 9.4% of the population (3.7 million) were diagnosed in 2021, with a notable gender disparity, further accentuates the expansion trajectory of the remote patient monitoring devices industry.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising incidence of chronic diseases across the globe
    • 3.2.1.2 Growing disposable income and healthcare expenditure in emerging countries
    • 3.2.1.3 Technological advancement in developed nations
    • 3.2.1.4 Growing adoption of remote patient monitoring devices
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of devices
    • 3.2.2.2 Stringent regulatory framework
• 3.3 Growth potential analysis
• 3.4 Technology landscape
• 3.5 Regulatory landscape
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Competitive dashboard
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Cardiac monitoring devices
• 5.3 Blood pressure monitoring devices
• 5.4 Neurological monitoring devices
• 5.5 Respiratory monitoring devices
• 5.6 Multiparameter monitoring devices
• 5.7 Blood glucose monitoring devices
• 5.8 Fetal and neonatal monitoring devices
• 5.9 Sleep monitoring devices
• 5.10 Other monitoring devices

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Cardiovascular diseases
• 6.3 Cancer
• 6.4 Diabetes
• 6.5 Neurological disorders
• 6.6 Infectious diseases
• 6.7 Respiratory diseases
• 6.8 Other applications

Chapter 7 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Home-care settings
• 7.3 Long-term care
• 7.4 Other end-users

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Russia
  • 8.3.7 Poland
  • 8.3.8 Switzerland
  • 8.3.9 Netherlands
  • 8.3.10 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Thailand
  • 8.4.7 Indonesia
  • 8.4.8 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
  • 8.5.4 Colombia
  • 8.5.5 Chile
  • 8.5.6 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE
  • 8.6.4 Israel
  • 8.6.5 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 Abbott Laboratories
• 9.2 Cerner Corporation
• 9.3 Baxter International Inc.
• 9.4 Boston Scientific Corporation
• 9.5 DexCom, Inc.
• 9.6 F. Hoffmann-La Roche Ltd
• 9.7 General Electric Company
• 9.8 Johnson and Johnson
• 9.9 Koninklijke Philips N.V
• 9.10 Medtronic plc
• 9.11 OMRON Corporation
• 9.12 Siemens Healthineers AG
• 9.13 VitalConnect